Top Health Care Stocks <\/p>\n
JNJ +0.33% <\/p>\n
PFE -0.88% <\/p>\n
ABT +0.01% <\/p>\n
MRK -0.30% <\/p>\n
AMGN +0.53% <\/p>\n
Health care stocks were higher this afternoon with the NYSE Health Care Sector Index climbing about 0.4% and shares of health care companies in the S&P 500 ahead by 0.2% as a group. <\/p>\n
In company news, Karyopharm Therapeutics ( KPTI ) fell again Thursday, more than matching its 10% slide yesterday despite the clinical-stage drugmaker today launching Phase IIb testing of its experimental treatment for certain types of lymphoma. <\/p>\n
The company previously received Orphan Drug designation for its Selinexor drug candidate from authorities in the United States and Europe as a treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma. <\/p>\n
The new, open-label trial is expected to enroll around 200 patients worldwide and will evaluate Selinexor's safety and efficacy in large and mid-sized oral doses, both as a single agent and in combination with an anti-inflammatory and immunosuppressant drug, dexamethasone. Testing is expected to take about two years. <\/p>\n
<\/p>\n
Original post: <\/p>\n
Health Care Sector Update for 12\/11\/2014: KPTI,ABIO,MEIP<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Top Health Care Stocks JNJ +0.33% PFE -0.88% ABT +0.01% MRK -0.30% AMGN +0.53% Health care stocks were higher this afternoon with the NYSE Health Care Sector Index climbing about 0.4% and shares of health care companies in the S&P 500 ahead by 0.2% as a group. In company news, Karyopharm Therapeutics ( KPTI ) fell again Thursday, more than matching its 10% slide yesterday despite the clinical-stage drugmaker today launching Phase IIb testing of its experimental treatment for certain types of lymphoma. The company previously received Orphan Drug designation for its Selinexor drug candidate from authorities in the United States and Europe as a treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma Continue reading